Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH

Trial Profile

Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions
  • Acronyms BACH
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 11 Sep 2013 Additional lead centre Merck added as reported by ClinicalTrials.gov.
    • 21 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top